Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

University of Michigan

1991, Ann Arbor, MI

Medical School

Kansas City University of Medicine and Biosciences

1999, Kansas City, MO

Internship

Internal Medicine and Pediatrics

Cleveland Clinic

Cleveland, OH

Residency

Internal Medicine and Pediatrics

Cleveland Clinic

Cleveland, OH

Fellowship

Pulmonary Medicine

Boston Children's Hospital

2006, Boston, MA

Certifications

  • American Board of Internal Medicine (General)

Media

Parentcast Podcast

Dr. Ahmet Uluer is featured: Should I transition my teen to an adult provider?

Publications

  1. Sepsis beyond bundles: contextualising paediatric care in resource-limited settings through situational analysis. BMJ Paediatr Open. 2025 Feb 12; 9(1). View Abstract

  2. Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers. J Cyst Fibros. 2025 Jan 22. View Abstract

  3. Cystic Fibrosis Experience of Care Survey: Patient-Caregiver-Clinician Collaborative Design and Implementation. J Patient Exp. 2024; 11:23743735241302739. View Abstract

  4. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy. Chest. 2025 Feb; 167(2):348-361. View Abstract

  5. Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. Front Nutr. 2024; 11:1441201. View Abstract

  6. Health care transition quadruple aim outcomes for IDD: Scoping review. Health Care Transit. 2024; 2:100067. View Abstract

  7. Healthcare transition readiness of families of youth with cystic fibrosis during COVID-19: A correlational multicenter analysis. Health Care Transit. 2024; 2:100065. View Abstract

  8. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Front Endocrinol (Lausanne). 2024; 15:1293709. View Abstract

  9. De novo mutations mediate phenotypic switching in an opportunistic human lung pathogen. bioRxiv. 2024 Feb 06. View Abstract

  10. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Diabetes Care. 2024 Jan 01; 47(1):101-108. View Abstract

  11. Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities. Sci Rep. 2023 09 12; 13(1):15030. View Abstract

  12. Development and Validation of a Respiratory-Responsive Vocal Biomarker-Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case-Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19. J Med Internet Res. 2023 04 14; 25:e44410. View Abstract

  13. Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis. J Cyst Fibros. 2023 09; 22(5):796-803. View Abstract

  14. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Lancet Respir Med. 2023 06; 11(6):550-562. View Abstract

  15. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1444-e1454. View Abstract

  16. The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Nutrients. 2022 Jan 12; 14(2). View Abstract

  17. Issues affecting young people with asthma through the transition period to adult care. Paediatr Respir Rev. 2022 Mar; 41:30-39. View Abstract

  18. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):1026-1034. View Abstract

  19. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022 03; 21(2):258-263. View Abstract

  20. Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 09; 18(9):1588-1592. View Abstract

  21. Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol. 2022 02; 57 Suppl 1:S75-S88. View Abstract

  22. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261. View Abstract

  23. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123. View Abstract

  24. Integration of mental health screening and treatment into cystic fibrosis clinics: Evaluation of initial implementation in 84 programs across the United States. Pediatr Pulmonol. 2020 11; 55(11):2995-3004. View Abstract

  25. Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the COVID-19 Pandemic. J Adolesc Health. 2020 09; 67(3):453-455. View Abstract

  26. Children's Hospitals Caring for Adults During a Pandemic: Pragmatic Considerations and Approaches. J Hosp Med. 2020 05; 15(5):311-313. View Abstract

  27. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study. Lancet Respir Med. 2019 12; 7(12):1027-1038. View Abstract

  28. Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Chest. 2019 06; 155(6):1226-1233. View Abstract

  29. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. View Abstract

  30. Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View Abstract

  31. A Pilot Study of Inspiratory Muscle Training to Improve Exercise Capacity in Patients with Fontan Physiology. Semin Thorac Cardiovasc Surg. 2018 Winter; 30(4):462-469. View Abstract

  32. Overcoming barriers to a successful transition from pediatric to adult care. Pediatr Pulmonol. 2017 Nov; 52(S48):S52-S60. View Abstract

  33. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clin Transl Gastroenterol. 2017 Mar 16; 8(3):e81. View Abstract

  34. Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. J Pediatr Gastroenterol Nutr. 2016 11; 63(5):e92-e97. View Abstract

  35. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View Abstract

  36. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View Abstract

  37. Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis. PLoS One. 2015; 10(8):e0135237. View Abstract

  38. Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. J Cyst Fibros. 2015 Jul; 14(4):526-32. View Abstract

  39. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View Abstract

  40. An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples. Lab Chip. 2014 Mar 21; 14(6):1087-98. View Abstract

  41. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros. 2013 Jan; 12(1):54-9. View Abstract

  42. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18; 363(21):1991-2003. View Abstract

  43. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View Abstract

  44. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009 Dec; 8(6):418-24. View Abstract

  45. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009 Jul; 141(1):86-90. View Abstract

  46. Recovery of Herbaspirillum species from persons with cystic fibrosis. J Clin Microbiol. 2008 Aug; 46(8):2774-7. View Abstract

  47. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med. 2008 Mar; 14(3):120-33. View Abstract

  48. Polymerase chain reaction/denaturing gradient gel electrophoresis (PCR/DGGE): sensitivity, band pattern analysis, and methodologic optimization. Am J Dermatopathol. 1999 Dec; 21(6):547-51. View Abstract

  49. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 1997 Feb; 280(2):576-83. View Abstract

  50. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther. 1995 Dec; 275(3):1638-46. View Abstract

  51. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. 1995 Jul; 105(1):51-5. View Abstract

  52. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol. 1995 Mar; 47(3):450-7. View Abstract

  53. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar; 268(3):1403-10. View Abstract
BESbswy